Shortages and price variability of essential cytotoxic medicines for treating children with cancers.

Problems with the availability of essential medicines, dependable supply chains, confidential medicine prices and wide variability in treatment costs contribute to persistent challenges in the care of children with treatable cancers, especially in LMICs.